SAN DIEGO, May 30, 2018 /PRNewswire/ -- Imprimis
Pharmaceuticals, Inc.'s (NASDAQ: IMMY) ophthalmology compounding
division, ImprimisRx, is pleased to announce the findings from a
study published in the Journal of Cataract and Refractive Surgery
in January 2018, which followed 483
eyes with glaucoma that were undergoing cataract surgery with
concomitant trabecular microbypass stent insertion. The study
was initially presented at the American Society of Cataract and
Refractive Surgery (ASCRS) and examines post-surgery outcomes for
patients receiving an intravitreal injection of steroid and
antibiotics at the time of surgery compared with a standard drop
regimen following surgery.
All study participants were diagnosed with primary open-angle
glaucoma and received a glaucoma stent at the time of surgery in
parallel with the cataract surgery procedure. The study group
of 234 eyes received an intravitreal injection (pars plana) of 0.2
mL of Dropless®, a combination of steroid and antibiotics, at the
time of surgery. The control group of 249 eyes received a
standard topical regimen postoperatively.
To evaluate safety, the incidence of intraocular pressure (IOP)
spikes was also recorded, which was defined as an increase of at
least 15 mm Hg from baseline IOP. There was no statistically
significant difference in the rate of IOP spikes between the two
groups. The safety profiles of both groups were favorable. In
the study group, there were no reported cases of inflammation,
cystoid macular edema (CME), infection or retinal detachments.
Imprimis CEO, Mark L. Baum,
commented, "The publication of this study of one of our Dropless®
formulations in one of the most prestigious peer-reviewed
ophthalmology journals validates the experiences of hundreds of
thousands of patients over the past four years. This
formulation continues to be an important option for patients and
doctors alike, to help reduce or eliminate the need for
post-surgery eye drop regimens and the potential for complications
with medication adherence."
About Imprimis Pharmaceuticals
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) is dedicated to
making high-quality innovative medications accessible and
affordable. The company's flexible business model allows a
drug to be compounded or developed as an FDA-approved product
through one of its subsidiaries or deconsolidated companies. For
more information about Imprimis, please visit the Investor
Relations section of the corporate website by clicking here.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995. Any statements in this release that are not historical facts
may be considered such "forward-looking statements."
Forward-looking statements are based on management's current
expectations and are subject to risks and uncertainties which may
cause results to differ materially and adversely from the
statements contained herein. Some of the potential risks and
uncertainties that could cause actual results to differ from those
predicted include our ability to make commercially available our
compounded formulations and technologies in a timely manner or at
all; physician interest in prescribing our formulations; risks
related to our compounding pharmacy operations; our ability to
enter into other strategic alliances, including arrangements with
pharmacies, physicians and healthcare organizations for the
development and distribution of our formulations; our ability to
obtain intellectual property protection for our assets; our ability
to accurately estimate our expenses and cash burn, and raise
additional funds when necessary; risks related to research and
development activities; the projected size of the potential market
for our technologies and formulations; unexpected new data, safety
and technical issues; regulatory and market developments impacting
compounding pharmacies, outsourcing facilities and the
pharmaceutical industry; competition; and market conditions. These
and additional risks and uncertainties are more fully described in
Imprimis' filings with the Securities and Exchange Commission,
including its Annual Report on Form 10-K and its Quarterly Reports
on Form 10-Q. Such documents may be read free of charge on the
SEC's web site at www.sec.gov. Undue reliance should not be placed
on forward-looking statements, which speak only as of the date they
are made. Except as required by law, Imprimis undertakes no
obligation to update any forward-looking statements to reflect new
information, events or circumstances after the date they are made,
or to reflect the occurrence of unanticipated events.
Imprimis's Dropless® compounded formulation is
not FDA-approved. Other than drugs compounded at a registered
outsourcing facility, all Imprimis compounded formulations require
a prescription for an individually identified patient consistent
with federal and state laws.
Source: Imprimis Pharmaceuticals, Inc.
Investor Contact
Jon
Patton
jpatton@imprimispharma.com
858.704.4587
Media Contact
Deb
Holliday
Holliday Communications, Inc.
deb@hollidaycommunications.net
412.877.4519
View original content with
multimedia:http://www.prnewswire.com/news-releases/imprimisrxs-dropless-steroid-and-antibiotic-intravitreal-injection-featured-in-the-prestigious-journal-of-cataract-and-refractive-surgery-300656202.html
SOURCE Imprimis Pharmaceuticals, Inc.